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Cancer cells evolve several alterations in their 
metabolism to survive in unfavorable microen­
vironments, while retaining their ability to pro­
liferate (Vander Heiden et al., 2009). A classical 
metabolic adaptation of tumor cells is a shift to 
aerobic glycolysis as a main source of ATP, rather 
than oxidative phosphorylation (OXPHOS), ir­
respective of oxygen availability, a phenomenon 
referred to as the Warburg effect (Warburg, 
1956). This phenotype may promote a state of 
apoptosis resistance (Plas and Thompson, 2002; 
Kroemer and Pouyssegur, 2008), the generation 
of  biosynthetic  precursors  for  proliferation 
(Vander Heiden et al., 2009), and increased in­
vasive ability (Stern et al., 2002). The molecular 
basis of aerobic glycolysis remains elusive and 
may vary across cancers. Genetic and epigenetic 
alterations in key enzymes resulting in metabolic 
modification include primary mutations, altered 
isoform expression profile, and altered regula­
tion/function secondary to oncogenic signal­
ing pathways or the tumor microenvironment 
(Vander Heiden et al., 2009).
An example of alterations in the isoform 
expression profile of metabolic enzymes is ex­
emplified by a switch in splice isoforms from 
the adult pyruvate kinase muscle 1 (PKM1) to 
the fetal PKM2, which is believed to promote 
aerobic glycolysis and tumor growth in lung 
cancer cell lines (Christofk et al., 2008). Primary 
mutations in isocitrate dehydrogenase-1 (IDH1),   
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Proliferating embryonic and cancer cells preferentially use aerobic glycolysis to support 
growth, a metabolic alteration commonly referred to as the “Warburg effect.” Here, we 
show that the glycolytic enzyme hexokinase 2 (HK2) is crucial for the Warburg effect in 
human glioblastoma multiforme (GBM), the most common malignant brain tumor. In con-
trast to normal brain and low-grade gliomas, which express predominantly HK1, GBMs 
show increased HK2 expression. HK2 expression correlates with worse overall survival of 
GBM patients. Depletion of HK2, but neither HK1 nor pyruvate kinase M2, in GBM cells 
restored oxidative glucose metabolism and increased sensitivity to cell death inducers such 
as radiation and temozolomide. Intracranial xenografts of HK2-depleted GBM cells showed 
decreased proliferation and angiogenesis, but increased invasion, as well as diminished 
expression of hypoxia inducible factor 1 and vascular endothelial growth factor. In con-
trast, exogenous HK2 expression in GBM cells led to increased proliferation, therapeutic 
resistance, and intracranial growth. Growth was dependent on both glucose phosphoryla-
tion and mitochondrial translocation mediated by AKT signaling, which is often aberrantly 
activated in GBMs. Collectively, these findings suggest that therapeutic strategies to modu-
late the Warburg effect, such as targeting of HK2, may interfere with growth and thera-
peutic sensitivity of some GBMs.
© 2011 Wolf et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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PKM2, restored normal oxidative glucose metabolism with 
decreased  extracellular  lactate  and  increased  expression  of 
OXPHOS proteins and O2 consumption. HK2 depletion re­
duced in vitro and in vivo growth of GBMs, with increased 
sensitivity to apoptosis induced by hypoxia, radiation, or che­
motherapy.  Furthermore,  the  growth­promoting  effects  of 
HK2 require both glucose phosphorylation and mitochondrial 
localization, mediated by activation of the PI3K–AKT signaling 
pathway, which is known to be aberrant in GBMs (Gottlob   
et al., 2001; Pastorino et al., 2002; Majewski et al., 2004).
RESULTS
Human GBMs express HK2, correlating with poor  
overall survival
To establish whether HK2 is expressed in human GBM sam­
ples, Western blot for HK2 expression was performed on 3 
normal human brains, 5 LGA and 12 GBM specimens (Fig. 1 A). 
At least eight of the GBM specimens expressed HK2, whereas 
normal human brains and LGAs only expressed HK1. Immuno­
histochemical staining of HK2 on a survival tissue micro­
array of 56 primary and secondary GBMs demonstrated that 
35 (62.5%) expressed HK2, whereas 21 (37.5%) did not (Cohen’s 
 = 0.81; P < 0.005; Guo et al., 2009). HK2 expression cor­
related with a poorer prognosis, even when controlling for age 
(Fig. 1 B; Cox proportional hazard, P < 0.006).
To determine whether HK2 transcript varies with GBM 
subtype, we data mined the recently published significance 
analysis of microarrays from The Cancer Genome Atlas’s pair­
wise analysis comparing transcript expression across different 
GBM subtypes (Verhaak et al., 2010). HK2 expression was 
lowest in the neural subtype and strongest in the mesenchy­
mal subtype, where PTEN and NF1 mutations predominate. 
HK2 transcript was intermediate in expression in the proneu­
ral subtype, in which IDH1 mutations predominantly occur 
(Table S1). None of the 12 GBM specimens were found to 
express mutant IDH1 (Fig. S1 A). Overall, there does not ap­
pear to be a relationship between HK2 and mutant IDH1 in 
GBM tissues.
HK2 is strongly expressed in the perinecrotic region  
of human GBMs
Increased apoptosis would be predicted for the pseudopali­
sading perinecrotic hypoxic cells around central regions of 
GBMs. However, TUNEL staining on 25 paired center and 
periphery GBM samples demonstrated almost equivalent and 
low apoptotic indices (<1%; Fig. S1 B). Quantitative RT­PCR 
(qRT­PCR) on microdissected cells from 12 paired GBM 
center and periphery cryosections demonstrated higher HK2 
expression  in  the  central  pseudopalisading  versus  invading 
GBM cells of the periphery (Fig. 1 C; P = 0.04). HK1 expres­
sion was not differentially expressed (P = 0.20). Immunohis­
tochemical staining was performed on the 25 paired GBM 
specimens,  6  LGAs,  and  3  normal  brain  samples.  Normal 
brain white matter did not express HK2, LGAs expressed low 
to none, and 20/25 GBMs expressed high levels of HK2,   
especially in the pseudopalisading cells (Fig. S1 C).
a metabolic enzyme, was recently identified in glioblastoma 
multiforme (GBM; Parsons et al., 2008; Yan et al., 2009), 
which is the most common and lethal of all primary human 
central nervous system tumors (Mellinghoff et al., 2005; Stupp 
et al., 2005). High­throughput genomic screening of GBMs 
identified a point mutation (predominantly R132H) in the 
IDH1 gene in 12% of all GBMs (Parsons et al., 2008) and 
80% of low­grade astrocytomas (LGA) or secondary GBMs 
that developed from their malignant progression (Watanabe   
et al., 2009; Yan et al., 2009). Mutation in IDH1 results   
in neomorphic activity, producing a different metabolite,   
2­hydroxyglutaric acid, whereas wild­type IDH1 normally con­
verts isocitrate to ­ketoglutarate coupled with NADP+/ 
NADPH. The impact of this mutation and of the accumulation 
of the metabolite 2­hydroxyglutarate on GBM metabolism 
and glucose utilization and subsequent growth remains unclear 
(Dang et al., 2009; Zhao et al., 2009). However, >90% of GBMs 
are primary GBMs and the molecular basis of the Warburg 
effect in this subset of GBMs is under active investigation.
As denoted by “multiforme,” GBMs are pathologically 
heterogeneous with “central” regions of necrosis surrounded 
by florid cellular (pseudopalisading cells) and hypervascular­
ized regions under moderate levels of hypoxic stress (pO2, 
2.5–5%; Evans et al., 2004). GBMs also have “peripheral” re­
gions,  which  consist  of  invading  tumor  cells  into  normal 
brain. GBM cells are resistant to standard apoptotic­inducing 
therapies, including radiation and chemotherapy, and are 
highly invasive (Brat et al., 2004). GBMs demonstrate an ap­
proximately threefold increase in glycolysis relative to normal 
brain (Oudard et al., 1996), with variations across different 
GBM cell lines (Gorin et al., 2004; Griguer et al., 2005).
In this study, we provide evidence demonstrating that the 
glycolytic enzyme hexokinase 2 (HK2) is aberrantly expressed 
in GBMs and is an important mediator of aerobic glycolysis 
in GBMs, providing a proliferative and cell survival advantage. 
HK2 is expressed at basal levels in skeletal and adipose tissue, 
but negligently in normal brain, which predominantly ex­
presses HK1. Several transcription and growth factors known 
to promote GBM growth, including insulin growth factor, 
myc, glucagon, and cAMP, among others, also modulate HK2 
expression and activity with reduced or no effect on HK1 
expression (Mathupala et al., 1995; Mathupala et al., 2001). 
Hypoxia  inducible  factor  1  (HIF1)  up­regulates  many   
enzymes of the glycolytic pathway, including HK2, by bind­
ing to hypoxia­responsive elements (HREs) in the HK2 pro­
moter (Mathupala et al., 2001). In addition, GBMs are known 
to have aberrant activation of growth factor receptors and/or 
loss of PTEN activity (Mellinghoff et al., 2005) with subse­
quent activation of the PI3K–AKT pathway. Upon AKT activa­
tion, HK2 may undergo translocation to the outer mitochondrial 
membrane and interact with the permeability transition pore, 
which includes the voltage­dependent anion channel (VDAC) 
and Bax to promote cell survival (Gottlob et al., 2001; Pastorino 
et al., 2002; Majewski et al., 2004).
Results from this study demonstrate that inhibition of 
HK2, but not of the glycolytic enzymes HK1 or downstream JEM VOL. 208, February 14, 2011 
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was significantly decreased (Fig. 2 B; 
P  <  0.05),  whereas  the  change  in 
caspase 3 and 7 activity was insignifi­
cant in U87 cells (Fig. 2 C). How­
ever, under hypoxic conditions, there 
was a significant increase in caspase 3 
and 7 activity (Fig. 2 C; P < 0.05) 
and Annexin  V labeling on flow cyto­
metry in U87 cells (Fig. S2 D), indicating increased apop­
tosis as a result of transient HK2 knockdown. In addition, 
caspase 3 and 7 activity assay demonstrated that U87 and 
U373 cells depleted of HK2 were significantly more sensi­
tive to apoptosis induced by radiation (Fig. 2 C; P < 0.05). 
Of clinical relevance, HK2 knockdown decreased the via­
bility of GBM cells, particularly U87 cells, exposed to te­
mozolomide (TMZ), the only current chemotherapeutic 
drug with demonstrated clinical efficacy in GBMs (Fig. 2 D; 
Stupp et al., 2005).
To validate the importance of HK2 in proliferation and 
resistance to apoptosis in GBM cells, we depleted HK2 for   
7 d in GBM explants established by D. James (GBM6 and 
GBM8;  Fig. S3, A and B; Sarkaria et al., 2006), which have 
been cultured transiently and thus are not subject to genetic 
pressures arising as a result of continuous passages under high 
glucose and growth factor conditions. Depletion of HK2 in 
GBM6 and GBM8 cells after 7 d resulted in reduction in 
proliferation (fold difference in BrdU) to 60% of control 
cells. Depletion of HK2 synergized with radiation (P < 0.05) 
or TMZ  therapy  (P  <  0.01)  in  reducing  proliferation  of 
GBM6 cells, but not GBM8 cells (Fig. S3 C). Furthermore, 
GBM6 and GBM8 cells depleted of HK2 did not demon­
strate enhanced apoptosis, measured by caspase 3 and 7 activ­
ity, when treated with TMZ. However, the combination of 
radiation and HK2 inhibition resulted in elevated caspase 3 
and 7 activity in GBM6 and GBM8 cells (Fig. S3 D; P < 
0.05). To determine whether there exists a differential sensi­
tivity to HK2 depletion based on the level of HK2 over­
expression  in  GBM  cells,  we  transfected  U87  cells  (high 
expression) and U138 cells (lower expression) with 25 or 50 nM 
Our  laboratory  has  previously  established  a  GFAP:V12 
Ha­Ras genetically engineered mouse model in which mice 
are born normal but develop LGAs and high­grade astro­
cytomas  (HGA),  which  when  characterized  are  similar  to 
their human counterparts (Ding et al., 2001). Immunohisto­
chemical staining of HK2 on three LGAs and three HGAs 
from GFAP:V12Ha­Ras mice demonstrate expression of HK2 
in 0/3 LGA and 2/3 HGA (Fig. S1 D).
Knockdown of HK2 decreases GBM cell proliferation  
and sensitizes them to therapeutic and microenvironmental 
inducers of apoptosis
The stronger expression of HK2 within the harsher central 
microenvironments  suggests  that  it  may  be  providing  a   
survival advantage to GBM cells. To answer this, control 
scramble small interfering RNA (siRNA) and HK2siRNA 
were transfected into U87 and U373 human GBM cell 
lines  to  determine  whether  HK2  confers  a  proliferative 
and/or cell survival advantage. HK2 was almost completely 
abolished 72 h after transfection (Fig. 2 A), without any al­
teration in HK1 or PKM2 levels (Fig. S2 C). Cell viability, 
measured by sulphorhodamine B (SRB) assay and trypan 
blue exclusion, was lower in U87 and U373 HK2siRNA­
transfected cells (P < 0.005; Fig. S2 A ). The decrease in cell 
viability was further enhanced by 2% hypoxia (P < 0.005; 
Fig. S2 B), which did not alter the suppression of HK2 by 
HK2siRNA (Fig. S2 C). BrdU incorporation and caspase 3 
and 7 activity assays were undertaken to determine whether 
the decreased cell viability was caused by reduced prolifer­
ation, increased cell death, or both. In normoxic conditions, 
at  120  h  after  transfection  of  HK2siRNA,  proliferation   
Figure 1.  HK2 is expressed in human 
GBMs and is associated with decreased 
overall survival. (A) Western blot of HK2 
and HK1 in 3 normal human brains, 5 LGAs, 
and 12 GBMs. (B) The survival of 56 GBM 
patients was dichotomized by expression of 
HK2, as determined by tissue microarray 
staining, with age as covariate (Cox propor-
tional hazard, P = 0.006). Inset depicts 
scanned tissue microarray stained for HK2. 
(C) HK2 and HK1 mRNA was measured by 
qRT-PCR in paired GBM center and periphery 
relative to normal human brain (P = 0.04, 
Wilcoxon signed rank test). Western blot and 
qRT-PCR were performed in three indepen-
dent experiments.316 Hexokinase 2 in glioblastoma multiforme | Wolf et al.
potentially  mediate  the  effect  HK2 
depletion on GBM cell proliferation 
and death.
Knockdown of HK2 sensitizes  
GBM cells to apoptosis  
by increasing mitochondrial 
membrane permeability
To elucidate the mechanisms involved 
in HK2­mediated metabolic remodel­
ing, mitochondrial function, and resis­
tance  to  apoptosis,  HK2  was  stably 
depleted  using  two  different  short 
hairpin RNAs (shRNAs; HK2shRNA1 
and HK2shRNA2) in U87 GBM cells (PTEN null, over­
expressed AKT, and p53 wt) that express high levels of HK2   
(Fig. 3 A). Transmission electron microscopy and immunofluo­
rescence of live cells stained with a MitoTracker dye demon­
strated no difference in morphology or number of mitochondria 
between scramble (scr) shRNA and U87HK2shRNA1 and 
U87HK2shRNA2 ( Fig. S4, A and B). FACS analysis of   
cells stained with nonyl acridine orange demonstrated that 
mitochondrial mass also did not differ significantly between 
U87scr (1,906 ± 337), U87HK2shRNA1 (1,553 ± 307), and 
U87HK2shRNA2 (1,675 ± 289) cells.
HK2 has previously been reported to translocate to the 
mitochondria and interact with members of the permeabil­
ity transition pore at the outer mitochondrial membrane   
(Pastorino et al., 2002; Majewski et al., 2004). This translocation 
of HK2siRNA for 7 d. U87 cells were found to have greater 
reduction in cell viability compared with U138 cells at 25 and 
50 nM of HK2siRNA (Fig. S3 E). Similarly, U87 cells that 
expressed wild­type PTEN, an important regulator of growth 
factor signaling in GBMs, demonstrated reduced responsive­
ness to HK2 depletion compared with U87 cells in which 
PTEN is deleted (Fig. S3 E). Overall, these results support an 
important role of HK2 depletion in GBM cells that express 
varying levels of HK2 and the potential synergistic effects 
with radiation or TMZ, by impacting either proliferation or 
apoptosis, depending on the genetic background of GBM 
cells. GBM6 and GBM8 cells differ in respect to several im­
portant regulators of metabolism and mediators of response 
to TMZ, including status of the DNA repair enzyme MGMT 
and the expression of PTEN and p53 (Fig. S3 A), which may 
Figure 2.  Inhibition of HK2 sensitizes 
GBM cells to drug-, radiation-, and  
hypoxia-induced apoptosis. (A) Western 
blot of HK2 in U87 and U373 transfected  
72 h prior with either HK2 siRNA (50 nM) or 
scramble (scr) siRNA (50 nM). (B) BrdU  
incorporation was measured in U87 and 
U373 cells transfected with scramble or 
indicated HK2 siRNA (50 nM) over 5 d. 
Mock-transfected cells were treated with 
transfection reagent only. (C) Caspase 3 and 7 
activity was measured in U87 and U373 
cells transfected with scramble or HK2 
siRNA 72 h prior, and then treated with  
5 Gy radiation (12 h) or hypoxia (2%; 24 h), 
using a fluorometric assay quantifying 
DEVD cleavage by caspase 3 and 7 and 
quantified as fold difference in relative 
fluorescence units (RFU; excitation at  
498 nm, emission at 521 nm). (D) Cell  
viability of U87 and U373 cells transfected 
with scramble or HK2 siRNA 72 h prior and 
treated with TMZ (100 M), an oral alkylat-
ing agent used in the treatment of GBMs. 
Proliferation, cell viability, and caspase  
assays were performed in triplicate and 
represented as mean ± SEM of three inde-
pendent experiment. *, P < 0.05.JEM VOL. 208, February 14, 2011 
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an effect that was more pronounced under hypoxic condi­
tions (Fig. 3 C).
Stable loss of HK2 reverts GBM cells to normal oxidative 
glucose metabolism
To determine if decreasing HK2 reverts aerobic glycolysis to 
OXPHOS­dependent glucose metabolism, proteins, tran­
scription  factors,  O2  consumption,  and  by­products  of   
OXPHOS metabolism were evaluated in U87HK2shRNA1 
and U87HK2shRNA2 GBM cells. OXPHOS­associated pro­
teins involved in the electron transport chain (part of com­
plexes I/II/III/IV/V) were increased in both HK2­depleted 
U87  GBM  cell  lines,  compared  with 
those  transfected  with  control  scr 
shRNA (Fig. 3 A). qRT­PCR evalu­
ation of key transcriptions factors in­
volved in mitochondrial function and 
biogenesis (peroxisome­proliferator­
activated  receptor­  co­activator   
[PGC1]; mitochondrial transcription 
factor A [mTFA]), demonstrated higher 
expression  after  HK2  knockdown, 
compared with scr shRNA (P < 0.05; 
and  interaction  regulates  the  release  of  cytochrome  c,  a   
critical step in the intrinsic apoptotic pathway (Majewski   
et al., 2004). To determine the effect of stable loss of HK2   
on  mitochondrial  membrane  potential  under  hypoxic   
conditions, live U87 cells were stained with the ratiomet­
ric  indicator  JC­1  and  analyzed  by  confocal  microscopy. 
Greater  depolarization  in  U87HK2shRNA1  cells  (Fig.  3  B)   
was observed compared with U87scr, as reflected by signifi­
cant reduction in the red:green fluorescence ratio (P = 
0.014). Furthermore, cytosolic cytochrome c level mea­
sured on ELISA were greater in both U87HK2shRNA1 and 
U87HK2shRNA2 cells, compared with U87scr (P < 0.05), 
Figure 3.  Stable loss of HK2 alters mito-
chondrial function, including a return to 
OXPHOS and increased expression of 
genes involved in mitochondrial biogen-
esis. (A) Western blot of HK2, HK1, PKM2, and 
OXPHOS proteins in U87 cells transfected 
with scramble (scr) shRNA, HK2shRNA1, or 
HK2shRNA2. (B) U87 cells transfected with 
scramble or HK2shRNA were subjected to  
24 h of 2% hypoxia. Red, J-aggregates; green, 
monomers reflecting mitochondrial mem-
brane depolarization. Bright field and merged 
images are also shown. Bars, 16 µm. Bar 
graph shows the mean ratio of red:green 
fluorescent signal intensities measured for  
10 cells/group in three independent experi-
ments (P = 0.014). (C) Cytosolic cytochrome c 
levels (ng/ml), relative to total protein content 
(microgram/milliliter), in indicated U87 cells 
were measured under normoxic and 2% hy-
poxic conditions (24 h) by ELISA. (D) PGC1 
and mTFA mRNA in indicated U87 cells was 
measured by qRT-PCR. (E) O2 consumption in 
indicated U87 cells (nmol O2/million cells/min) 
was measured using Clark-type oxygen elec-
trode monitoring dissolved oxygen concentra-
tion in a sealed chamber over time.  
(F) Extracellular lactate in indicated U87 cells 
was measured by a NADH-coupled enzyme 
reaction with absorbance measured at 490 nm, 
and normalized to cell number. qRT-PCR,  
O2 consumption, and lactate measurements 
were performed in triplicates and graphs 
show mean ± SEM of three independent ex-
periments. *, P < 0.05; **, P < 0.01.318 Hexokinase 2 in glioblastoma multiforme | Wolf et al.
phosphorylation and mitochondrial binding) were transfected 
into U343 cells. Overexpression of HK2­GFP in U343 cells 
provided protection against radiation­induced apoptosis, re­
flected by a smaller increase in cytosolic cytochrome c and 
caspase 3 and 7 activity compared with cells expressing mu­
tant or truncated HK2 (Fig. 4, C and D). Similarly, prolifera­
tion of U343 HK2­GFP cells was increased compared with 
control (GFP) and U343 HK1­GFP–expressing cells after 3 d 
of +EGF (Fig. 4 E). Both U343 T2­GFP and M2­GFP had 
decreased proliferation compared with HK2­GFP, suggesting 
that both glucose phosphorylation and the N­terminal mito­
chondrial binding domain contribute to HK2’s proliferative 
effects, although glucose phosphorylation does so to a greater 
extent (Fig. 4 E).
Differential role of HK2 versus HK1 or PKM2 on GBM 
metabolism and proliferation
To  determine  whether  HK1,  which  like  HK2  converts 
glucose to glucose­6­phosphate (Wilson, 2003), or PKM2,   
another  downstream  rate­limiting  glycolytic  enzyme,  also 
regulate aerobic glycolysis in GBMs, shRNAs toward HK1 
and PKM2 were generated in U87 human GBM lines (Fig. 5 A). 
Total HK activity level was reduced compared to control 
U87 cells expressing scr shRNA in cells depleted of HK2 
and HK1 (Fig. 5 B). Similar to loss of HK2, loss of HK1 and 
PKM2 did not alter mitochondrial number or morphology 
(Fig. S4 B). However, unlike HK2, depleted HK1 or PKM2 
did not reduce extracellular lactate (Fig. 5 C) or increase O2 
consumption (Fig. 5 D). Expression of pyruvate dehydroge­
nase E1  (PDHE1a), an enzyme that plays a key role in the 
function of the PDH complex, which catalyzes the conver­
sion of pyruvate to acetyl­coA in the mitochondria to un­
dergo OXPHOS, was elevated with loss of HK2 but not 
HK1 (Fig. 5 A). Furthermore, overexpression of HK1­GFP 
in U87 cells depleted of HK2 (Fig. 5 A) did not rescue extra­
cellular lactate (Fig. 5 C) or inhibit OXPHOS restoration 
seen with HK2 knockdown (Fig. 5 D). Overexpression stud­
ies in U343 cells, which do not express HK2 and minimally 
express HK1, were also in support of HK2 and not HK1   
being the major regulator of aerobic glycolysis in GBMs. In 
addition to enhanced proliferation, HK2­GFP overexpres­
sion increased extracellular lactate levels by 11% by day 3 
compared  with  control  cells  (normalized  to  cell  number;   
Fig. 4 F), which was not observed in HK1­GFP overexpres­
sion. This was irrespective of total HK activity, which was 
similar between U343­transfected HK2­GFP and HK1­GFP 
cells (Fig. S5 C).
To verify that the decrease in lactate production with de­
pletion of HK2 is not solely caused by reduced glucose up­
take, cells were stained with the fluorescent d­glucose analogue   
2­[N­(7­nitrobenz­2­oxa­1,3­diazol­4­yl)amino]­2­deoxy­
d­glucose. Interestingly, GBM cells depleted of HK2 showed 
a significant compensatory increase in glucose uptake, as   
did U87HK1shRNA to a lesser extent, whereas cells depleted 
of PKM2 had reduced glucose uptake compared with U87 
scr shRNA (Fig. 5 E). Enhanced glucose uptake was associated 
Fig. 3 D). Evidence of a switch to OXPHOS­based metabolism 
was a greater than twofold increase in O2 consumption (Fig. 3 E) 
and reduction of extracellular lactate (Fig. 3 F) in cells lacking 
HK2 compared with scr shRNA.
Translocation of HK2, and not HK1, to the outer 
mitochondrial membrane after growth factor stimulation 
increases proliferation and generation of lactate
Previous studies have demonstrated that growth factor stimu­
lation, resulting in activation of the PI3K–AKT pathway, 
promotes translocation of HK2 to the outer mitochondrial 
membrane, resulting in increased protein stability (Bustamante 
and Pedersen, 1977; Gottlob et al., 2001). To test this in GBM 
cells, U87 cells were treated with the protein synthesis inhibi­
tor cycloheximide (CHX) with or without EGF stimulation. 
Without EGF, more than half of HK2 protein was degraded by 
12 h of CHX treatment, whereas HK2 protein levels were main­
tained for up to 20 h when incubated with EGF (Fig. S5 D).
To evaluate HK2 and HK1 translocation to the mito­
chondria, U343 GBM cells (HK2 –ve and HK1 +ve; no   
tumor formation in mice) and U87 GBM cells (+HK2 and 
+HK1; grow in vivo) were transfected to express HK1­GFP 
or HK2­GFP with or without EGF stimulation. U343 HK2­
GFP (green) after +EGF showed greater colocalization to 
mitochondria (blue; white, R = 80 ± 8.9%) compared to 
EGF conditions (R = 52 ± 12%; Fig. 4 A). Treatment of 
U343 cells with AKT inhibitor VIII (2 M) for 6 h under 
growth factor conditions showed reduced colocalization of 
HK2 with mitochondria by immunofluorescence (R = 53 ± 
6%) and mitochondrial fractionation (Fig. 4,  A and B). In con­
trast, HK1­GFP was found predominantly at mitochondria, 
irrespective of EGF stimulation (EGF, R = 85 ± 7%; +EGF, 
R = 83 ± 8%). In U87 cells, a greater proportion of HK2­
GFP localized to the mitochondria under EGF conditions 
(R = 74 ± 14%; +EGF = 81 ± 12%; Fig. S5 A) compared 
with U343 cells. This is likely a reflection of higher basal 
pAKT levels in U87 cells, which can be induced with EGF 
stimulation in U343 cells (Fig. S5 B). In support, inhibition of 
PI3K–AKT activation with AG1478 (2 M EGFR inhibitor) 
in U87 cells decreased HK2 localization to the mitochondria 
(R = 45 ± 9%; Fig. S5 A), as did treatment of U87 cells with 
AKT inhibitor VIII (R = 59 ± 10%). U87 cells in which 
PTEN has been reintroduced also show reduced mitochon­
drial localization of HK2 (R = 58 ± 6%; Fig. S5 A). Similar to 
U343 cells, HK1­GFP localization was predominantly mito­
chondrial and not altered by EGF (EGF, R = 83 ± 11%; 
+EGF, R = 84 ± 12%).
We next determined the importance of the catalytic func­
tion and mitochondrial translocation of HK2 on cell death 
and growth of U343 cells, which do not express HK2 endog­
enously.  Previously  characterized  HK2  mutant  constructs 
(Sun et al., 2008; M2, lacks the catalytic domains required to 
phosphorylate glucose, but can translocate to bind mitochon­
dria; T2, lacks the N­terminal mitochondrial­binding domain, 
but can phosphorylate glucose; TM2, lacks ability for glucose JEM VOL. 208, February 14, 2011 
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depletion of HK2. Interestingly, depletion 
of total PKM2 resulted in elevated total 
HK activity (Fig. 5 B), suggesting com­
pensatory mechanisms engaged by cells to 
increase glucose flux, yet resulting in mod­
est but not significant increases in lactate 
levels and a small increase in PDHE1a ex­
pression (Fig. 5, A and C).
Lastly, we wished to determine whether depletion of 
HK2, HK1 or PKM2 glycolytic enzymes in GBM cells may 
have resulted in compensatory increase in the alternatively 
spliced PKM1, expressed in normal brain and associated 
with OXPHOS (Christofk et al., 2008). To address this, we 
performed a PKM2 splice assay (David et al., 2010) and 
found that the percentage of PKM2 over total PKM1 AND 
PKM2 did not change significantly with loss of HK2 or HK1 
(Fig. 5 G). However, the overexpression of HK1 in cells   
with  increased  GLUT1  expression  at  the  transcript  level   
in cells depleted of HK2 and HK1 (Fig. 5 F). Furthermore, 
HK2­depleted cells showed significantly reduced LDHA 
transcript  expression,  correlating  with  the  reduction  in 
lactate (Fig. 5 F).
Although glucose flux was not measured directly, the 
increase in PDHE1a expression coupled with enhanced 
O2 consumption and decreased lactate levels suggest there 
is  greater  flux  of  glucose  to  oxidative  metabolism  with   
Figure 4.  Growth factor–PI3K-AKT signaling is 
important for localization of HK2, but not HK1, 
to outer mitochondrial membrane and necessary 
for the growth-promoting effects of HK2.  
(A) Immunofluorescence of U343 cells transfected 
with HK2-GFP or HK1-GFP, under starved, EGF- 
stimulated conditions or treated with the AKT inhibi-
tor VIII for 6 h (2 µM). U343 cells were also 
transfected truncated HK2-GFP that does not local-
ize to the mitochondria (T2-GFP). Mitochondria are 
labeled with MitoTracker Deep Red (blue). Mitochon-
drial colocalization is seen in white in merged  
images. Bars, 16 µm. The percentage of colocaliza-
tion was measured across 5–10 cells in two indepen-
dent experiments. (B) Mitochondrial fractionation of 
U343 cells transfected with HK2-GFP, with or with-
out treatment with the AKT inhibitor VIII (2 µM) for  
6 h. VDAC is a marker of the mitochondrial fraction 
and vinculin of the cytosolic fraction. C, cytosolic;  
M, mitochondria. Fractionation and Western blot 
were performed in two independent experiments.  
(C) Caspase 3 and 7 activity in U343 cells transfected 
with HK2-GFP, T2-GFP, M2-GFP, or TM2-GFP and 
treated with 5 Gy radiation was measured using a 
fluorometric assay quantifying DEVD cleavage by 
caspase 3 and 7 and represented as fold difference 
in relative fluorescence units (RFU; excitation at 498 
nm, emission at 521 nm). (D) Cytosolic cytochrome c 
levels in U343 cells transfected with HK2-GFP,  
T2-GFP, M2-GFP, or TM2-GFP and treated with 5 Gy 
radiation were measured using ELISA of fractionated 
cells lysate. (E) BrdU incorporation was measured in 
U343 cells overexpressing HK2-GFP, HK1-GFP,  
T2-GFP, M2-GFP, TM2-GFP, or control (GFP only).  
(F) Extracellular lactate in cells overexpressing HK2-
GFP, HK1-GFP, or control (GFP only) was measured 
by NADH-coupled enzyme reaction with absorbance 
measured at 490 nm on day 3 and normalized to cell 
number. BrdU, caspase 3 and 7, and lactate mea-
surements were performed in triplicates and graphs 
show mean ± SEM of three independent experi-
ments. *, P < 0.05; **, P < 0.01.320 Hexokinase 2 in glioblastoma multiforme | Wolf et al.
HK2 regulates growth  
and angiogenesis in orthotopic 
xenograft models of GBM
Stereotactic  intracranial  injections   
of  U87  controls  (U87  scr  shRNA   
or  U87­empty  vector,  n  =  10), 
U87HK2shRNA  tagged  with  RFP   
(n = 10), U87 overexpressing HK2­
GFP (n = 10) or a mixed U87 HK2shRNA­RFP+U87HK2­
GFP group (n = 6) were undertaken. Mice injected with 
U87HK2shRNA­RFP  survived  significantly  longer  than 
those injected with either U87 controls, U87HK2­GFP or 
mixed cells (P < 0.01; Fig. 6 A). HK2 overexpressing mice   
or the mixed group did not live as long as the U87 controls 
(P < 0.01). Although there was no difference in survival and 
pathology  between  the  U87HK2­GFP  and  mixed  group, 
only the U87HK2­GFP cells were observed in mixed tumors, 
reflecting a growth advantage for cells overexpressing HK2 
(Fig. 6, A, B, and D).
The  majority  of  tumors  with  decreased  HK2  did  not 
form large tumors (Fig. 6 B). However, U87HK2shRNA­
RFP tumor cells invaded the perivascular Virchow­Robin 
spaces and tracked along leptomeninges in both hemispheres, 
a phenomenon not seen in control tumors. Tumor cells that 
were depleted of HK2 could even be found deep within the 
depleted of HK2 resulted in the suppression of PKM2 to 
levels similar to PKM2shRNA cells.
Subcutaneous growth of HK2-deficient GBM cells  
is impaired
To determine the effect of stable loss of HK2 on in vivo 
subcutaneous xenografts, U87 scr shRNA (n = 7) or U87 
HK2shRNA  cells  (1  and  2;  n  =  4  each)  were  injected 
subcutaneously into NOD­SCID mice. By 4 wk, the scr 
shRNA group had substantial tumors, whereas no visible 
tumor was seen in mice injected with U87HK2shRNA 
(Fig. S6 A). At 8 wk, 3/8 U87HK2shRNA­injected mice 
remained tumor free (P < 0.001; Fig. S6 A). The scr shRNA 
tumors showed large regions of necrosis (N) and HIF1 
positivity with decreased apoptosis as measured by cleaved 
caspase  3  compared  with  U87HK2shRNA1  xenografts   
(1 vs. 4%; Fig. S6 B).
Figure 5.  Differential role of HK2, HK1, 
and PKM2 in GBM mitochondrial metabo-
lism and survival. (A) Western blot of HK2, 
HK1, PKM2, and PDHe1a in U87 cells trans-
fected with scramble shRNA, HK2shRNA1, 
HK1shRNA, PKM2shRNA, or U87HK2shRNA 
and HK1-GFP. Bands are taken from the same 
noncontiguous gel. WT, wild type HK1.  
(B) Total HK activity normalized to scramble 
shRNA in cells described in panel A. (C) The 
extracellular lactate in cells described in A was 
measured by NADH-coupled enzyme reaction 
with absorbance measured at 490 nm on day 3 
and normalized to cell number. (D) O2 con-
sumption in cells described in A (nmol O2/
million cells/min) was measured using Clark-
type oxygen electrode monitoring dissolved 
oxygen concentration in a sealed chamber 
over time. (E) Glucose uptake in cells from 
panel A measured by incubation with the 
glucose analogue 2-NBDG followed by flow 
cytometry. (F) GLUT1 and LDHA mRNA mea-
sured by qRT-PCR in cells described in panel A.  
(G) PKM splicing assay was performed on cells 
from panel A. Splice assay consists of PCR of 
PKM, followed by digestion with the enzyme 
PstI, generating products corresponding to 
the M1 and M2 isoforms. The percentage of 
M2 over total PKM is depicted below. All ex-
periments represent mean ± SEM of three 
independent experiments. *, P < 0.05;  
**, P < 0.01JEM VOL. 208, February 14, 2011 
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Figure 6.  HK2 regulates GBM growth and invasion in an orthotopic xenograft model. (A) Survival curve of mice injected intracranially with 2 × 105 
of U87 cells expressing HK2shRNA-RFP (n = 10), U87 control cells (n = 10), U87 cells overexpressing HK2-GFP (n = 10), or a mix of U87 cells express-
ing HK2-GFP and HK2shRNA-RFP (n = 6). (B) Hematoxylin and eosin stain of tumors described in A. Bars, 2,000 µm. Arrow is pointing to the small tumor 
in HK2shRNA-RFP tumors. (C) Hematoxylin and eosin micrographs depicting invasiveness of HK2shRNA tumors. The arrow is pointing at the invading 
tumor cells within the cerebellum. Bars: (top) 250 µm; (bottom) 100 µm. Bottom graph depicts the extent of invasiveness of tumors depicted in panel B, 
which was determined by measuring the mean distance (micrometers) of invading tumor clusters away from the main tumor mass. (D) Top immunofluo-
rescence of GFP and RFP (blue, DAPI) in U87HK2-GFP, U87 mixed, and U87HK2shRNA-RFP tumors. Bar, 28 µm. Bottom immunofluorescence of staining of 
the vasculature (vWF) of tumors. Bar, 39 µm. (E) Histopathology of U87HK2-GFP, U87 control, and U87HK2shRNA intracranial tumors with antibodies 
specific to vWF (blood vessels labeled with arrow; bar, 100 µm), VEGF (bar, 100 µm), HIF1 (positive cells labeled with arrow; bar, 50 µm), MIB1  
(bar, 100 µm), cleaved caspase 3 (bar, 100 µm). The percentage of proliferating cells (MIB1) and apoptotic cells (cleaved caspase 3) are indicated above  
the photomicrographs.322 Hexokinase 2 in glioblastoma multiforme | Wolf et al.
cerebellum (Fig. 6 C). The extent of invasion, as quantified by 
measuring the mean distance (micrometer) of invading tumor 
clusters away from the tumor mass, was increased in both 
U87HK2­GFP  and  U87HK2shRNA­RFP  tumors  com­
pared with U87 controls (P < 0.01; Fig. 6 C). However, inva­
sion by the overexpressing HK2 tumor cells was more local in 
the adjacent parenchyma.
The tumor vasculature (vWF positivity) was reduced in 
U87HK2shRNA­RFP, with RFP­tagged tumor cells migrat­
ing along existing normal brain vessels (Fig. 6, D and E).   
In comparison, U87HK2­GFP tumors showed numerous ir­
regularly shaped and distorted vessels, especially at the leading 
edge (Fig. 6, D and E), in contrast to the smaller vessels found 
throughout the U87 control tumors. The U87HK2­GFP and 
U87 controls, in contrast to HK2 depleted tumors, showed 
sporadic expression of HIF1 and expression of vascular en­
dothelial growth factor (VEGF; Fig. 6 D). U87HK2shRNA­
RFP tumors had a decreased proliferative index (MIB1, 34.2 ± 
4.4%; Fig. 6, E and F), whereas the U87HK2­GFP tumors   
had a higher proliferative index (64.4 ± 8.8%), even com­
pared with U87 controls (47.5 ± 2.5%; Fig. 6, E and F). 
Cleaved caspase 3 levels were elevated in tumors with re­
duced HK2 (12 ± 3%) compared with control (3 ± 1.3%) and 
HK2­GFP (2 ± 1.5%; Fig. 6 E). In summary, inhibition of 
HK2 restricted growth of human GBMs within the intracra­
nial environment, with decreased angiogenesis but enhanced 
perivascular invasion.
Because of decreased HIF1 seen in subcutaneous and 
intracranial tumors (Fig. 6 and Fig. S6), we wished to deter­
mine whether HK2 depletion decreases HIF1 levels by   
altering either its synthesis or its degradation by prolyl hy­
droxylases  (PHD).  qRT­PCR  of  cells  depleted  of  HK2   
revealed no significant difference in synthesis of HIF1 tran­
script (Fig. S6 C). Interestingly, PHD2 protein expression was 
found to be increased in cells depleted of HK2, suggesting 
there may be greater degradation of HIF1 protein (Fig. S6 D). 
Further supporting the decrease in angiogenesis seen in vivo, 
cells depleted of HK2 showed reduced intracellular VEGF 
levels (Fig. S6 D).
DISCUSSION
Proliferating  cells  use  aerobic  glycolysis  to  assist  in  their 
growth (Vander Heiden et al., 2009). In several types of can­
cer, a shift to aerobic glycolysis occurs with active suppression 
of OXPHOS. This metabolic switch may be reversible and 
partly result from aberrant regulation of glycolytic enzymes 
(Bonnet  et  al.,  2007;  Gatenby  and  Gillies,  2004;  Plas  and 
Thompson, 2002). Therefore, a better understanding of the 
drivers of the Warburg effect is of biological and therapeutic 
interest. Results of this study collectively show HK2 to be a 
major regulator of aerobic glycolysis in GBMs.
Consistent with published microarray data (Dong et al., 
2005; Parsons et al., 2008) and The Cancer Genome Atlas   
dataset, we demonstrate aberrant expression of HK2 in a large 
percentage of GBMs (Fig. 1, A and B), with minimal expres­
sion in normal brain or LGAs. GBMs that express HK2 have 
a poorer overall survival. Mining of the Repository of Mo­
lecular Brain Neoplasia Data (REMBRANDT), in which 
human glioma samples have been collected from patients en­
rolled in the Glioma Molecular Diagnostic Initiative study, 
corroborates our prognostic results that HK2 predicts poor 
overall survival in glioma patients (REMBRANDT, 2005).   
In addition, there was regional variation within GBMs, with 
greater  HK2  expression  in  the  highly  proliferating  and 
apoptosis­resistant perinecrotic central regions compared with 
the invading peripheral GBM cells (Fig. 1 C and Fig. S1 C). 
This suggests that HK2 may provide a survival and prolifer­
ative advantage in vivo, especially within harsher tumor   
microenvironments. There does not appear to be a relationship 
between  GBM  samples  expressing  HK2  compared  with   
mutant IDH1 based on our results and TCGA subtype analy­
sis (Verhaak et al., 2010).
Our in vitro experiments demonstrated that transient in­
hibition of HK2 in GBM cells decreased proliferation and 
sensitized cells to therapeutic apoptotic stimuli such as radio­
therapy and the chemotherapeutic oral alkylating agent TMZ 
(Fig. 2, C and D; and Fig. S3, C and D). Stable depletion of 
HK2 inhibited aerobic glycolysis and promoted normal oxi­
dative glucose metabolism, as exemplified by decreased extra­
cellular lactate, increased expression of OXPHOS proteins 
and increased O2 consumption (Fig. 3). In support of this, 
overexpression of HK2 promoted proliferation, resistance to 
apoptosis, and lactate formation (Fig. 4). The addition of HK1   
to cells lacking HK2 resulted in the rescue of total HK activ­
ity, but did not rescue the phenotype of aerobic glycolysis in 
GBM cells (Fig. 5, A–D), supporting a unique role of HK2 
over HK1 in GBM growth. Similarly, depletion of the down­
stream rate­limiting enzyme PKM2 did not significantly alter 
lactate levels or oxygen consumption in GBM cells. However, 
this study did not examine the impact on metabolism of the 
rescue of GBM cells depleted of PKM2 with expression of 
adult PKM1 splice isoform, previously shown to impact aero­
bic glycolysis (Christofk et al., 2008).
The exact mechanisms of how HK2 inhibits OXPHOS 
and promotes proliferation and lactate formation remain un­
clear; however, both glucose phosphorylation and mitochon­
drial localization contributed to these effects, as demonstrated 
by expression of HK2 mutants in GBM cells (Fig. 4). HK2 has 
been previously shown to interact with VDAC at the mito­
chondria and regulate the release of cytochrome c and apop­
tosis, although the mechanistic details regarding opening or 
closure of permeability transition pore (and associated de­
polarization or hyperpolarization of mitochondria) and the 
release of cytochrome c are not well understood (Pastorino   
et al., 2002; Majewski et al., 2004). Notably, HK2 transloca­
tion is regulated by growth factor–induced oncogenic signaling 
pathways, such as increased EGFR and PI3K–AKT activation, 
known to be aberrant in GBMs (Mellinghoff et al., 2005). 
Mitochondrial binding of HK2 also alters its expression and 
function by reducing feedback inhibition from its end prod­
uct, glucose­6­phosphate, to increase its stability (Fig. S5 D) 
and  promote  glycolytic  flux  and  overall ATP  levels  by   JEM VOL. 208, February 14, 2011 
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using  VEGF, HIF1 , and HK2 inhibitors are warranted to see 
if there is a synergistic effect and more importantly, if com­
bining these treatments can negate the invasive escape pheno­
type when these inhibitors are used as mono therapies.
In summary, inhibition of HK2 in GBMs results in resto­
ration of normal oxidative glucose metabolism in association 
with decreased HIF1 and VEGF expression, resulting in im­
paired tumorigenic growth and reduced angiogenesis. The 
mechanisms underlying the enhanced invasiveness with de­
pletion of HK2 are subject to further investigations, including 
the determination of whether this effect is HIF1 and/or 
VEGF dependent. This altered metabolism was not observed 
with loss of HK1, and is suggestive of aberrant HK2 expres­
sion being an important regulator of aerobic glycolysis in 
GBMs, but does not rule out the possibility of its working in 
conjunction with other specific downstream glycolytic en­
zyme isoforms. Exploiting tumor cells dependence on the 
Warburg effect by altering or reprogramming cell metabolism 
provides an attractive therapeutic approach. Because HK2 ex­
pression is limited in the normal adult brain, with HK1 being 
the predominant isoform, targeting HK2 or its function may 
be a way of selectively killing GBM cells while limiting toxic­
ity to surrounding normal tissue. Current agents targeting 
HK2 (e.g., 3­bromopyruvate, 2­deoxyglucose) may have lim­
ited clinical potential caused by nonspecificity (e.g., target 
HK1 or other metabolic proteins as well) and systemic toxic­
ity. To circumvent this, specific inhibitors of HK2 or of its   
mitochondrial translocation that can be administered using 
local delivery strategies already used in GBM clinical trials 
(Ferguson and Lesniak, 2007) should be developed. The intra­
cranial xenograft data suggests that although overall growth 
and survival is improved by genetic inhibition of HK2 and 
rectification of normal glucose metabolism, increased inva­
sion may be a long­term consequence, which may impact the 
therapeutic suitability of targeting the Warburg effect singu­
larly. However, selectively targeting of the Warburg effect in 
GBM with current modalities of treatment may provide syn­
ergism and enhance overall treatment efficacy. Whether the 
increased sensitivity to radiation and chemotherapy conferred 
by reduction of HK2, as in in vitro results, offsets this longer 
term increased invasion, will require further interrogation.
MATERIALS AND METHODS
Human GBM samples. Stereotactically guided GBM samples were ac­
quired. These were verified by C. Hawkins, co­author and neuropatholo­
gist, for the presence of perinecrotic pseudopalisading tumor cells (center) 
and infiltrating tumor cells (periphery). Approval from the University 
Health Network Research Ethics Board was obtained for research on   
human samples.
qRT-PCR. Total RNA was extracted from frozen tissue samples or GBM 
cells using the RNEasy kit (QIAGEN), and cDNA was synthesized using the 
QuantiTect RT kit (QIAGEN). qRT­PCR was performed using SYGR 
green (Invitrogen) and the Chromo4 Real Time PCR detector (Bio­Rad 
Laboratories). The following primers were used: HK1, 5­GGACTGGACC­
GTCTGAATGT­3  and  5­ACAGTTCCTTCACCGTCTGG­3;  HK2, 
5­CAAAGTGACAGTGGGTGTGG­3 and 5­GCCAGGTCCTTCA­
CTGTCTC­3;  HPRT1,  5­TGACACTGGCAAAACAATGCA­3  and 
preferentially using mitochondrial ATP (Bustamante and 
Pedersen, 1977). In contrast to HK2, HK1 mitochondrial lo­
calization was not regulated by growth factor signaling path­
ways in GBMs (Fig. 4 and Fig. S5). Our data supports that 
HK2 suppresses both apoptosis and oxidative metabolism, al­
though the temporal order of events and mechanisms linking 
mitochondrial membrane depolarization, enhanced OXPHOS, 
release of cytochrome c, and decreased proliferation with loss 
of HK2 require further investigation. Putative mechanisms 
may include interaction between altered mitochondrial mem­
brane permeability, generation of reactive oxygen species, and 
activation of cell cycle inhibitors such as TP53 or P21CIP1, 
among other events. One possible effector mechanism through 
which depletion of HK2 can promote a return to OXPHOS 
is  by  increased  expression  of  the  transcription  factors 
PGC1 and mTFA, which are important for the expression of   
metabolic­associated genes such as OXPHOS genes (Fig. 3 D). 
PGC1 has previously been shown to act as a dominant reg­
ulator of mitochondrial function, respiration, and biogenesis 
(Rohas et al., 2007).
Reduction of HK2 expression in GBM cells also had in 
vivo antitumorigenic effects in both subcutaneous and intra­
cranial xenograft models (Fig. 6 A and Fig. S6 A). Mixing 
experiments  with  HK2­depleted  and  HK2­overexpressing 
GBM cells clearly demonstrated a proliferative advantage of 
the latter (Fig. 6, A and D). Both subcutaneous and intracra­
nial HK2­depleted GBM xenografts grew slowly and had in­
creased apoptosis (Fig. 6 E and Fig. S6 B). However, they 
differed in one potentially important aspect; the small intra­
cranial  GBM  tumors  with  HK2  knockdown  were  much 
more invasive and tracked along perivascular spaces deep in 
both hemispheres (Fig. 6, B–D). This difference may reflect 
the poorly vascularized subcutaneous environment compared 
with the highly vascular intracranial microenvironment. The 
increased invasive nature intracranially is reminiscent of the 
longer­term effects of VEGF inhibition and antiangiogenic 
therapies on GBM growth in intracranial models and human 
clinical trials (Blouw et al., 2003; Paez­Ribes et al., 2009).   
A possible molecular explanation of the increased invasion by 
GBMs with HK2 knockdown may relate to HIF1, which 
was decreased relative to control tumors or tumors over­
expressing  HK2.  Reduction  of  HIF1  would  inhibit  its 
transcriptional targets such as VEGF and provide a plausible 
explanation  of  the  phenotypic  similarity  between  HK2 
knockdown, VEGF, or HIF1 knockdown in in vivo GBM 
models (Blouw et al., 2003; Paez­Ribes et al., 2009). In sup­
port of this, it has been reported that GBMs with HIF1 
knockdown grow poorly subcutaneously, but grow highly in­
vasive tumors intracranially (Blouw et al., 2003). The decrease 
in HIF1 that we see in vivo in our tumors lacking HK2 may 
be caused by the fact that these tumors never grow beyond a 
size prompting HIF1 stabilization from microenvironmental 
influences. Alternatively, we show that HK2­depleted GBM 
cells express less VEGF and HIF1 in vitro, the latter linked 
with greater expression of PHD2, potentially hastening its 
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Mitochondrial membrane permeability and immunofluorescence. 
Mitochondrial membrane potential was assessed with JC­1 dye (Invitrogen). 
Cells were grown on coverslips, incubated under normoxic or hypoxic con­
ditions for 24 h, and loaded for 20 min with 2 µM of JC­1 in HBSS at 37°C. 
Cells were then washed in PBS, maintained at 37°C, and excited with 540 
and 488 nm lasers to visualize the aggregate and monomer signals, respec­
tively. The mean ratios of red versus green fluorescent signal intensities (relative 
pixel intensity) were measured for 10 U87 HK2shRNA1 and 10 U87 scram­
ble shRNA cells in 3 independent experiments. Immunofluorescence of live 
cells stained with 50 nM of MitoTracker Deep Red (Invitrogen) for 20 min 
was also performed. Images were taken on an Axiovert 200 (Carl Zeiss, Inc.) 
equipped with a Hamamatsu Orca AG CCD camera and spinning disk con­
focal scan head using Volocity acquisition software. Regions of interest were 
drawn on the image data and the software. We then summed the chosen pix­
els to generate a fluorescence ratio or percentage of colocalization. Signal 
within the nucleus was used as background fluorescence.
Western blot analysis. Cell lines were lysed in modified PLC lysis buffer 
and protein concentration determined using the BCA assay (Thermo Fisher 
Scientific). Membranes were probed overnight with the following antibodies: 
­actin (1:20,000; Sigma­Aldrich); PDH­E1a (1:200; Abcam); VEGF (1:200; 
Santa Cruz Biotechnology, Inc.,); HIF1 (1:250; BD); and PKM2, HK2, 
HK1, and PHD2 (1:1,000; Cell Signaling Technology). The OXPHOS cock­
tail of antibodies (1:200; Mitoscience) targets the following proteins: 20­kD 
subunit of Complex I (20 kD), COX II of Complex IV (22 kD), 30­kD Ip 
subunit of Complex II (30 kD), core 2 of complex III (50 kD), and F1 
(ATP synthase) of Complex V (60 kD).
Mitochondrial fractionation and cytochrome c ELISA. 10 million 
U87  scramble  shRNA,  U87  HK2shRNA1,  and  U87HK2shRNA2  were 
harvested and fractionated into cytosolic and mitochondrial fractions using a 
mitochondrial fractionation kit (Thermo Fisher Scientific). ELISA for cyto­
chrome c was performed on the cytosolic fraction according to the manufac­
turer’s protocol (R&D Systems) and was normalized to total protein content.
Oxygen consumption and lactate and glucose uptake assays. Lactate 
assay was performed according to manufacturer’s protocol and normalized to 
cell number (Eton Bioscience). For glucose uptake, 1 million cells were 
stained with fluorescent d­glucose analogue 2­[N­(7­nitrobenz­2­oxa­1,3­
diazol­4­yl) amino]­2­deoxy­d­glucose (2­NBDG; 100 µM; Invitrogen) for 
30 min, washed with PBS, and analyzed by flow cytometry. O2 consumption 
was measured using a model 110 Fiber optic oxygen monitor (Instech). Cells 
were trypsinized and counted, and 5 million cells were resuspended in 500 µl 
of media, warmed at 37°C. Measurements were made in triplicates in three 
independent experiments and reported as nmol O2/million cells/min.
HK assay. HK activity was measured as previously described (Ahmad et al., 
2002). Cells were lysed using the following buffer: 50 mM potassium phos­
phate, 2 mM dithiothreitol (DTT), 2 mM EDTA, and 20 mM sodium fluo­
ride. 1 ml of buffer was used to harvest 5 million cells. After the cells were 
harvested, the cell homogenate was incubated on ice for 30 min, followed by 
centrifugation at 1,000 g at 4°C for 10 min. Approximately 10 µl of freshly 
lysed cell supernatant was added to 1,000 µl of 100 mM Tris­HCl, pH 8.0, 
0.5 mM EDTA, 10 mM ATP, 10 mM MgCl2, 2 mM glucose, 0.1 mM NADP, 
and 0.1 U/ml of G6PD (Sigma­Aldrich). HK activity was determined by 
following the G6P­dependent conversion of NADP to NADPH spectro­
photometrically at 340 nm at 37°C. One activity unit is defined as micro­
moles of NADPH per milliliter per minute at 37°C.
Subcutaneous GBM xenograft model. Animal studies were performed 
with the approval of the Hospital for Sick Children. NODSCID mice were 
injected  subcutaneously  with  1.5  ×  106  U87  scr  shRNA  (n  =  7)  or 
U87HK2shRNA1 and 2 cells (n = 4 each). Mice were observed for tumor 
formation, and then sacrificed. Tumors were harvested at 4 wk (U87 scr 
shRNA) or 8 wk (U87HK2shRNA1, 2).
5­GGTCCTTTTCACCAGCAAGCT­3; PGC1, 5­TCAGTCCTCAC­
TGGTGGACA­3  and  5­TGCTTCGTCGTCAAAAACAC­3;  mTFA, 
5­AATGGATAGGCACAGGAAACC­3 and 5­CAAGTATTATGCTG­
GCAGAAGTC­3;  HIF1,  5­CGTTCCTTCGATCAGTTGTC­3  and 
5­TCAGTGGTGGCAGTGGTAGT­3.
Immunohistochemistry. Immunohistochemical staining was performed 
on formalin­fixed, paraffin­embedded 5­µm thick GBM tissue. Citrate antigen 
retrieval was performed. Overnight incubation at 4°C with primary anti­
body was performed (Table S2). Detection was performed using VectaStain 
ABC reagent and DAB chromogen (Vector Laboratories). TUNEL immuno­
histochemistry  was  performed  with  the  DeadEnd  colorimetric TUNEL   
System (Promega). The apoptotic index (percentage) was calculated as the 
number of positive nuclei over total nuclei. GBM tissue microarray with 
prognostic information was acquired from P. Mischel (University of Califor­
nia, Los Angeles, Los Angeles, CA) and stained with HK2. An interrater   
reliability analysis using Cohen’s  statistic was performed to determine con­
sistency among ratings. Mutant IDH1 antibody was generously provided by 
A. von Deimling (University of Heidelberg, Heidelberg, Germany).
Cell lines. The U87 (p53 wt) and U373 (p53mut; obtained from D. Bigner, 
Duke University, Durham, NC) and U343 GBM lines were maintained in 
DME, 10% FBS, and antibiotics. Hypoxic conditions were achieved by incu­
bating cells in a tissue culture incubator flushed with N2, 5% CO2, and O2 
levels maintained constant at 2% using an oxygen controller (ProOx; Bio­
spherix Ltd). Cells were transfected with either 50 nM of HK2 siRNA or   
50 nM of scramble siRNA, or mock­transfected using HiPerFect transfection 
reagent (QIAGEN). In overexpression studies, cells were transfected with 
HK1­GFP  and  HK2  constructs  provided  by  H. Ardehali  (Northwestern 
University, Evanston, IL) using FuGENE transfection reagent (Roche). Cells 
were treated with AG1478 (EMD) for 24 h at 2 µM or AKT inhibitor VIII 
(EMD) for 6 h at 2 µM.
Cell viability assay and BrdU incorporation assay. Cell viability was 
measured using the SRB colorimetric assay (Sigma­Aldrich) and trypan blue 
exclusion. Proliferation was measured by BrdU incorporation assay (Pro­
mega) according to the manufacturer’s protocol. For BrdU, cells were nor­
malized to a standard curve of known concentration of cells.
Determination of apoptosis. Cells were seeded into a 96­well plate, trans­
fected with siRNA, and at 3 d after transfection administered 5 Gy radiation 
or 24 h of 2% hypoxia. Caspase 3 and 7 activity levels were measured using 
the Apo­One Homogeneous caspase 3 and 7 assay (Promega). This assay in­
cludes a profluorescent caspase 3 and 7 consensus substrate and rhodamine 
110 containing a DEVD peptide substrate sequence that, upon cleavage, be­
comes fluorescent when excited at a wavelength of 498 nm. The emission 
maximum is 521 nm. The amount of fluorescent product generated is repre­
sentative of the amount of active caspase 3 and 7 present in the sample. 
Apoptosis was also assessed with fluorescence­activated cell sorting analysis 
(FACScan; BD) of live cells stained with Annexin V­FITC/PI (BD).
Generation of stable cell lines. Target sequences from HK2 siRNA 1 and 
2 were used to design shRNA. shRNA for HK2, HK1, PKM2, and scramble 
shRNA were annealed and then cloned into RNAi Ready pSIREN­retroQ 
vector (Takara Bio Inc.). The following siRNA target sequences were used: 
HK2,  siRNA1  5­CACGATGAAATTGAACCTGGT­3;  HK2,  siRNA2 
5­CCTGGGTGAGATTGTCCGTAA­3.  The  HK1  shRNA  sequence 
used  was  5­CACGATGTAGTCACCTTACTA­3. The  PKM2  shRNA 
target  sequence  used  was  5­GCTGTGGCTCTAGACACTAAA­3. 
U87HK2shRNA cells were also stably transfected with HK1­GFP and U87 
cells with HK2­GFP, both provided by H. Ardehali. For PKM splicing assay, 
PCR of PKM was performed, followed by digestion with PstI (PKM exon 8 
forward, 5­CTGAAGGCAGTGATGTGGCC­3; PKM exon 11 reverse, 
5­ACCCGGAGGTCCACGTCCTC­3). Products were resolved on 2% 
agarose gel.JEM VOL. 208, February 14, 2011 
Article
325
Christofk,  H.R.,  M.G. Vander  Heiden,  M.H.  Harris, A.  Ramanathan,  R.E. 
Gerszten, R. Wei, M.D. Fleming, S.L. Schreiber, and L.C. Cantley. 2008. The 
M2 splice isoform of pyruvate kinase is important for cancer metabolism 
and tumour growth. Nature. 452:230–233. doi:10.1038/nature06734
Dang, L., D.W. White, S. Gross, B.D. Bennett, M.A. Bittinger, E.M. Driggers, 
V.R. Fantin, H.G. Jang, S. Jin, M.C. Keenan, et al. 2009. Cancer­associated 
IDH1  mutations  produce  2­hydroxyglutarate.  Nature.  462:739–744. 
doi:10.1038/nature08617
David, C.J., M. Chen, M. Assanah, P. Canoll, and J.L. Manley. 2010. HnRNP 
proteins controlled by c­Myc deregulate pyruvate kinase mRNA splic­
ing in cancer. Nature. 463:364–368. doi:10.1038/nature08697
Ding, H., L. Roncari, P. Shannon, X. Wu, N. Lau, J. Karaskova, D.H. Gutmann, 
J.A. Squire, A. Nagy, and A. Guha. 2001. Astrocyte­specific expression of 
activated p21­ras results in malignant astrocytoma formation in a trans­
genic mouse model of human gliomas. Cancer Res. 61:3826–3836.
Dong,  S.,  C.L.  Nutt,  R.A.  Betensky, A.O.  Stemmer­Rachamimov,  N.C. 
Denko, K.L. Ligon, D.H. Rowitch, and D.N. Louis. 2005. Histology­
based expression profiling yields novel prognostic markers in human 
glioblastoma. J. Neuropathol. Exp. Neurol. 64:948–955. doi:10.1097/01 
.jnen.0000186940.14779.90
Evans, S.M., K.D. Judy, I. Dunphy, W.T. Jenkins, P.T. Nelson, R. Collins, E.P. 
Wileyto, K. Jenkins, S.M. Hahn, C.W. Stevens, et al. 2004. Comparative 
measurements of hypoxia in human brain tumors using needle elec­
trodes and EF5 binding. Cancer Res. 64:1886–1892. doi:10.1158/0008­
5472.CAN­03­2424
Ferguson, S., and M.S. Lesniak. 2007. Convection enhanced drug delivery 
of novel therapeutic agents to malignant brain tumors. Curr. Drug Deliv. 
4:169–180. doi:10.2174/156720107780362302
Gatenby, R.A., and R.J. Gillies. 2004. Why do cancers have high aerobic   
glycolysis? Nat. Rev. Cancer. 4:891–899. doi:10.1038/nrc1478
Gorin, F., W. Harley, J. Schnier, B. Lyeth, and T. Jue. 2004. Perinecrotic 
glioma  proliferation  and  metabolic  profile  within  an  intracere­
bral tumor xenograft. Acta Neuropathol. 107:235–244. doi:10.1007/ 
s00401­003­0803­1
Gottlob, K., N. Majewski, S. Kennedy, E. Kandel, R.B. Robey, and N. Hay. 
2001. Inhibition of early apoptotic events by Akt/PKB is dependent on 
the first committed step of glycolysis and mitochondrial hexokinase. 
Genes Dev. 15:1406–1418. doi:10.1101/gad.889901
Griguer, C.E., C.R. Oliva, and G.Y. Gillespie. 2005. Glucose metabolism het­
erogeneity in human and mouse malignant glioma cell lines. J. Neurooncol. 
74:123–133. doi:10.1007/s11060­004­6404­6
Guo, D., I.J. Hildebrandt, R.M. Prins, H. Soto, M.M. Mazzotta, J. Dang, J. 
Czernin, J.Y. Shyy, A.D. Watson, M. Phelps, et al. 2009. The AMPK ago­
nist AICAR inhibits the growth of EGFRvIII­expressing glioblastomas 
by inhibiting lipogenesis. Proc. Natl. Acad. Sci. USA. 106:12932–12937. 
doi:10.1073/pnas.0906606106
Kroemer,  G.,  and  J.  Pouyssegur.  2008. Tumor  cell  metabolism:  cancer’s 
Achilles’ heel. Cancer Cell. 13:472–482. doi:10.1016/j.ccr.2008.05.005
Majewski, N., V. Nogueira, P. Bhaskar, P.E. Coy, J.E. Skeen, K. Gottlob, N.S. 
Chandel, C.B. Thompson, R.B. Robey, and N. Hay. 2004. Hexokinase­
mitochondria interaction mediated by Akt is required to inhibit apop­
tosis in the presence or absence of Bax and Bak. Mol. Cell. 16:819–830. 
doi:10.1016/j.molcel.2004.11.014
Mathupala, S.P., A. Rempel, and P.L. Pedersen. 1995. Glucose catabolism in   
cancer cells. Isolation, sequence, and activity of the promoter for type II   
hexokinase.  J.  Biol.  Chem.  270:16918–16925.  doi:10.1074/jbc.270 
.28.16918
Mathupala, S.P., A. Rempel, and P.L. Pedersen. 2001. Glucose catabolism in 
cancer cells: identification and characterization of a marked activation 
response of the type II hexokinase gene to hypoxic conditions. J. Biol. 
Chem. 276:43407–43412. doi:10.1074/jbc.M108181200
Mellinghoff, I.K., M.Y. Wang, I. Vivanco, D.A. Haas­Kogan, S. Zhu, E.Q. Dia, 
K.V. Lu, K.  Yoshimoto, J.H. Huang, D.J. Chute, et al. 2005. Molecular de­
terminants of the response of glioblastomas to EGFR kinase inhibitors. 
N. Engl. J. Med. 353:2012–2024. doi:10.1056/NEJMoa051918
Oudard, S., F. Arvelo, L. Miccoli, F. Apiou, A.M. Dutrillaux, M. Poisson, B. 
Dutrillaux, and M.F. Poupon. 1996. High glycolysis in gliomas despite 
low hexokinase transcription and activity correlated to chromosome 10 
loss. Br. J. Cancer. 74:839–845.
Intracranial GBM model. NODSCID mice were stereotactically injected 
with 200,000 cells of U87 control (U87 + empty vector and U87 scramble 
shRNA, n = 10), U87HK2shRNA + RFP, U87HK2­GFP (n = 10), or 
U87HK2­GFP + HK2shRNA­RFP (n = 6). Upon development of symp­
toms, mice were anesthetized and perfused with 4% PFA, and brains har­
vested followed by flash freezing or paraffin embedding.
Statistical analyses. qRT­PCR and in vitro experiments were performed 
in triplicates. Means and standard errors were computed. Student’s t test or 
Wilcoxon sign rank t test was performed to determine whether a significant 
difference exists between groups. Analysis of patient survival was performed 
using Kaplan­Meier plots generated in SPSS, using age as a covariate, and sta­
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Online supplemental material. Fig. S1 shows staining of HK2, mutant IDH1, 
and TUNEL in GBM samples. Fig. S2 shows that inhibition of HK2 results in 
decreased cell viability in GBM cells, including under hypoxia. Fig. S3 shows that 
inhibition of HK2 in GBM explants reduces proliferation and sensitizes to radia­
tion and TMZ. Fig. S4 shows no significant impact on mitochondrial structure 
and count in U87 cells depleted of HK2, HK1, or PKM2. Fig. S5 shows that 
growth factor–PI3K­AKT signaling is important for localization of HK2, but 
not HK1, to outer mitochondrial membrane, and is necessary for the growth 
promoting effects of HK2. Fig. S6 shows that stable loss of HK2 decreases in 
vivo GBM growth in a subcutaneous xenograft model, in addition to decreased 
HIF1 stability and  VEGF expression with inhibition of HK2.  Table S1 shows the 
pairwise comparison in expression of HK2 transcript across GBM subtypes using 
Significance Analysis of Microarrays (Verhaak et al., 2010). Table S2 lists the pri­
mary antibodies used for immunohistochemical staining with dilutions. shRNA 
and primer sequences are available upon request. Online supplemental material is 
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